ReviewSmall (Weinheim an der Bergstrasse, Germany)2026
Bioactive Gold Plasmonic Interfaces Meet Artificial Intelligence: Advancing Saliva-Based Surface-Enhanced Raman Spectroscopy Diagnostics.
Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bioactive gold plasmonic nanostructures are enabling non-invasive saliva diagnostics by amplifying weak Raman signals and converting complex biofluid chemistry into information-rich spectral fingerprints. This Review examines saliva-based Raman and surface-enhanced Raman spectroscopy (SERS) integrated with artificial intelligence (AI) from a bioactive-materials perspective. Saliva is positioned as a cross-disease liquid biopsy relevant to oncological, infectious, inflammatory, metabolic, neurodegenerative, and pulmonary disorders. Particular emphasis is placed on how gold nanostructure geometry, substrate architecture, surface functionalization, antifouling strategies, affinity capture, and protein-corona formation govern molecular access to electromagnetic hot spots, spectral reproducibility, and computational reliability. Case studies spanning oncology, infectious, inflammatory, and pulmonary disorders illustrate how substrate engineering and dataset construction jointly determine diagnostic performance and clinical portability. Because human studies combining saliva, gold-enabled SERS, and AI remain limited, explicit inclusion criteria distinguish direct salivary evidence from contextual studies using related biospecimens. Clinically viable saliva-based SERS diagnostics require coordinated co-design of bioactive plasmonic interfaces and computational pipelines, together with standardized pre-analytics, reproducible substrates, rigorous patient-level validation, shared datasets, and independent multicenter evaluation.
Indexed as
Identifiers
42734099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.